PETX - Aratana Therapeutics Stock Price, News & Analysis

$7.10 0.25 (3.65 %)
(As of 11/24/2017 02:40 AM ET)
Previous Close$6.85
Today's Range$6.82 - $7.24
52-Week Range$4.97 - $8.63
Volume233,300 shs
Average Volume391,000 shs
Market Capitalization$294.55 million
P/E RatioN/A
Dividend YieldN/A
Beta3.4

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.


Industry, Sector and Symbol

Industry Veterinary Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A

Debt

Debt-to-Equity Ratio0.26%
Current Ratio3.42%
Quick Ratio3.08%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.55 million
Price / Sales7.92
Cash FlowN/A
Price / CashN/A
Book Value$2.18 per share
Price / Book3.26

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.45)
Net Income$-33,570,000.00
Net Margins-358.55%
Return on Equity-48.79%
Return on Assets-30.52%

Miscellaneous

Employees85
Outstanding Shares43,000,000

Frequently Asked Questions for Aratana Therapeutics (NASDAQ:PETX)

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics, Inc. (NASDAQ:PETX) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.03. The biopharmaceutical company earned $6.16 million during the quarter, compared to analyst estimates of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The firm's revenue was up 1440.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.38) earnings per share. View Aratana Therapeutics' Earnings History.

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?

5 analysts have issued twelve-month target prices for Aratana Therapeutics' stock. Their predictions range from $7.00 to $10.00. On average, they expect Aratana Therapeutics' stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (11/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Q4'16 results uneventful. The Nocita and Galliprant launches are progressing and Entyce is on track for late '17 launch. However, we think the sell-off on the Q4 results was primarily driven by concerns around the cash runway and how this will be addressed. We like the risk/ reward at this level and reiterate our Buy rating. PT lowered to $8 (from $11)." (3/16/2017)
  • 3. Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:

  • Wendy L. Yarno, Chairman of the Board (Age 62)
  • Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
  • Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
  • Brent Standridge, Chief Operating Officer (Age 58)
  • Ernst Heinen Ph.D., Chief Development Officer (Age 52)
  • Laura A. Brege, Independent Director (Age 59)
  • David L. Brinkley, Independent Director (Age 57)
  • Robert Benthall Gerber Jr., Independent Director (Age 52)
  • Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
  • Merilee Raines, Independent Director (Age 61)

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.19%), Alyeska Investment Group L.P. (2.24%), General American Investors Co. Inc. (2.02%), Dimensional Fund Advisors LP (0.90%), Wells Fargo & Company MN (0.85%) and Cadence Capital Management LLC (0.40%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sheaff Brock Investment Advisors LLC and California State Teachers Retirement System. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Alyeska Investment Group L.P., Wells Fargo & Company MN, Janus Henderson Group PLC, Cadence Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of Aratana Therapeutics stock can currently be purchased for approximately $7.10.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $294.55 million and generates $38.55 million in revenue each year. The biopharmaceutical company earns $-33,570,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (PETX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aratana Therapeutics (NASDAQ:PETX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (26.76% upside)

Consensus Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Analysts' Ratings History for Aratana Therapeutics (NASDAQ:PETX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017HC WainwrightInitiated CoverageBuy -> Buy$10.00N/AView Rating Details
11/16/2017Jefferies Group LLCSet Price TargetBuy$9.00N/AView Rating Details
8/25/2017Lake Street CapitalLower Price TargetBuy -> Buy$15.00 -> $10.00LowView Rating Details
5/10/2017Stifel NicolausLower Price TargetBuy -> Buy$8.00 -> $7.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016Barclays PLCLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00N/AView Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Aratana Therapeutics (NASDAQ:PETX)

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Earnings History by Quarter for Aratana Therapeutics (NASDAQ PETX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.24)($0.21)$6.47 million$6.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aratana Therapeutics (NASDAQ:PETX)
2017 EPS Consensus Estimate: ($1.10)
2018 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.35)($0.29)($0.31)
Q2 20173($0.33)($0.28)($0.30)
Q3 20173($0.30)($0.24)($0.26)
Q4 20173($0.27)($0.19)($0.23)
Q1 20182($0.18)($0.16)($0.17)
Q2 20182($0.15)($0.13)($0.14)
Q3 20182($0.14)($0.09)($0.12)
Q4 20182($0.04)$0.25$0.11
Q1 20192($0.10)$0.03($0.04)
Q2 20192$0.02$0.06$0.04
Q3 20191$0.10$0.10$0.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aratana Therapeutics (NASDAQ PETX)

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 73.66%
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Insider Trades by Quarter for Aratana Therapeutics (NASDAQ PETX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Peter Steven StInsiderSell50,000$7.00$350,000.00View SEC Filing  
10/2/2017Peter Steven StInsiderSell50,000$6.24$312,000.00View SEC Filing  
9/25/2017Brent StandridgeCOOSell10,000$6.11$61,100.00View SEC Filing  
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aratana Therapeutics (NASDAQ PETX)

Source:
DateHeadline
Aratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 MillionAratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 Million
www.americanbankingnews.com - November 20 at 6:50 AM
Zacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 18 at 1:26 PM
Aratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLCAratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - November 18 at 12:52 PM
Aratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC WainwrightAratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - November 18 at 11:38 AM
Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 18 at 6:04 AM
Aratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group ForecastsAratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 17 at 8:30 PM
Aratana Therapeutics, Inc. (PETX) Receives Average Rating of "Hold" from BrokeragesAratana Therapeutics, Inc. (PETX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 6:42 AM
Peter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) StockPeter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) Stock
www.americanbankingnews.com - November 13 at 7:26 PM
Aratana Therapeutics (PETX) and Eli Lily (LLY) Division Elanco Animal Health Reports Positive Opinion on ... - StreetInsider.comAratana Therapeutics (PETX) and Eli Lily (LLY) Division Elanco Animal Health Reports Positive Opinion on ... - StreetInsider.com
www.streetinsider.com - November 12 at 11:35 AM
With three products out, Aratana chases its fourth: a canine cancer drugWith three products out, Aratana chases its fourth: a canine cancer drug
finance.yahoo.com - November 9 at 11:16 AM
FY2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX)FY2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX)
www.americanbankingnews.com - November 9 at 7:21 AM
William Blair Comments on Aratana Therapeutics, Inc.s FY2020 Earnings (PETX)William Blair Comments on Aratana Therapeutics, Inc.'s FY2020 Earnings (PETX)
www.americanbankingnews.com - November 8 at 10:44 PM
Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:37 AM
Aratana Therapeutics, Inc. (PETX) Rating Reiterated by Jefferies Group LLCAratana Therapeutics, Inc. (PETX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - November 5 at 5:40 PM
Your Daily Pharma Scoop: Timing Synergy Trade, Valeants Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking AlphaYour Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking Alpha
seekingalpha.com - November 4 at 8:51 AM
Your Daily Pharma Scoop: Timing Synergy Trade, Valeants Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking AlphaYour Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking Alpha
seekingalpha.com - November 4 at 8:51 AM
What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?
finance.yahoo.com - November 4 at 8:50 AM
What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics Reports Third Quarter 2017 Financial ResultsAratana Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics Reports Third Quarter 2017 Financial ResultsAratana Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 8:50 AM
Aratana reports 3Q lossAratana reports 3Q loss
finance.yahoo.com - November 4 at 8:50 AM
Aratana reports 3Q lossAratana reports 3Q loss
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. to Host Earnings CallAratana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. to Host Earnings CallAratana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:50 AM
ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 8:50 AM
ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 8:50 AM
Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:50 AM
Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. (PETX) Posts  Earnings Results, Beats Estimates By $0.03 EPSAratana Therapeutics, Inc. (PETX) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 3 at 6:24 PM
Aratana Therapeutics to Present at Credit Suisse Healthcare Conference - PR Newswire (press release)Aratana Therapeutics to Present at Credit Suisse Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 1 at 7:29 AM
Aratana Therapeutics to Present at Credit Suisse Healthcare ConferenceAratana Therapeutics to Present at Credit Suisse Healthcare Conference
finance.yahoo.com - October 31 at 7:48 AM
Aratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on WednesdayAratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:30 AM
Aratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of "Hold" from AnalystsAratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 2:26 PM
William Blair Weighs in on Aratana Therapeutics, Inc.s Q2 2018 Earnings (PETX)William Blair Weighs in on Aratana Therapeutics, Inc.'s Q2 2018 Earnings (PETX)
www.americanbankingnews.com - October 18 at 12:28 PM
Corporate News Blog - Aratana Therapeutics Launches ENTYCE (Capromorelin Oral Solution)Corporate News Blog - Aratana Therapeutics Launches ENTYCE (Capromorelin Oral Solution)
finance.yahoo.com - October 17 at 3:58 PM
Todays Research Reports on Stocks to Watch: Aratana Therapeutics and TG TherapeuticsToday's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics
finance.yahoo.com - October 17 at 3:58 PM
ETFs with exposure to Aratana Therapeutics, Inc. : October 17, 2017ETFs with exposure to Aratana Therapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 17 at 3:58 PM
Aratana Therapeutics, Inc. to Post Q1 2018 Earnings of ($0.20) Per Share, William Blair Forecasts (PETX)Aratana Therapeutics, Inc. to Post Q1 2018 Earnings of ($0.20) Per Share, William Blair Forecasts (PETX)
www.americanbankingnews.com - October 17 at 10:38 AM
Biotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight - Seeking AlphaBiotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight - Seeking Alpha
seekingalpha.com - October 17 at 6:12 AM
7 Stocks To Watch For October 16, 2017 - Benzinga7 Stocks To Watch For October 16, 2017 - Benzinga
www.benzinga.com - October 17 at 6:12 AM
Hungry for growth, Aratana takes new pet drug to marketHungry for growth, Aratana takes new pet drug to market
finance.yahoo.com - October 17 at 6:12 AM
Aratana Therapeutics (PETX) Launches ENTYCE to Stimulate Appetite in DogsAratana Therapeutics (PETX) Launches ENTYCE to Stimulate Appetite in Dogs
www.streetinsider.com - October 15 at 5:35 AM
Aratana Therapeutics Announces Launch of ENTYCE® (capromorelin oral solution)Aratana Therapeutics Announces Launch of ENTYCE® (capromorelin oral solution)
finance.yahoo.com - October 14 at 6:43 AM
Aratana Therapeutics to Report Third Quarter 2017 Financial ResultsAratana Therapeutics to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 5 at 8:46 PM
ETFs with exposure to Aratana Therapeutics, Inc. : October 3, 2017ETFs with exposure to Aratana Therapeutics, Inc. : October 3, 2017
finance.yahoo.com - October 5 at 3:44 PM
Aratana Therapeutics, Inc. (PETX) Insider Peter Steven St Sells 50,000 SharesAratana Therapeutics, Inc. (PETX) Insider Peter Steven St Sells 50,000 Shares
www.americanbankingnews.com - October 4 at 8:02 PM
Aratana Therapeutics, Inc. (PETX) COO Sells $61,100.00 in StockAratana Therapeutics, Inc. (PETX) COO Sells $61,100.00 in Stock
www.americanbankingnews.com - September 27 at 8:32 PM
Aratana Therapeutics, Inc. (PETX) Given Consensus Recommendation of "Hold" by BrokeragesAratana Therapeutics, Inc. (PETX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 27 at 2:32 PM
$5.77 Million in Sales Expected for Aratana Therapeutics, Inc. (PETX) This Quarter$5.77 Million in Sales Expected for Aratana Therapeutics, Inc. (PETX) This Quarter
www.americanbankingnews.com - September 23 at 9:50 AM

Social Media

Financials

Chart

Aratana Therapeutics (NASDAQ PETX) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.